Day: April 27, 2022

These rapid, sustained reductions in annualized relapse rate and risk of relapse with natalizumab treatment occurred regardless of baseline disease activity in the overall population and in the subset of patients with highly active disease. Observations from a clinical practice setting (TOP) were similar to the clinical trial results but should be interpreted with caution […]